JPM26: J&J leans on immunology launches to fuel annual growth [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
and Icotide, according to CEO Joaquin Duato speaking at the J.P. Morgan Healthcare Conference 2026. Excluding Stelara (ustekinumab), J&J Innovative Medicine grew 16% in Q3 2025, said Duato. Stelera, which peaked at around $11bn in revenue in 2023, has seen its market dominance eroded by biosimilar competition. Flexing assets that are picking up the lost revenue, performance in 2026 is expected to exceed the previous year for J&J, building “sustainable and deeper” growth via a broad portfolio that spans innovative medicine and medical technology. Duato highlighted Tremfya (guselkumab) as the company's most important asset within immunology, having had a successful launch in irritable bowel disease (IBD). The interleukin-23 (IL-23) blocking biologic is approved in indications in plaque psoriasis, active psoriatic arthritis, ulcerative colitis, and Crohn's disease. With access to large patient populations, Duato predicts Tremfya will be “bigger than Stelara” and worth more than $10bn
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Top Research Reports for AbbVie, Intel & Boeing [Yahoo! Finance]Yahoo! Finance
- AbbVie (NYSE:ABBV) had its "neutral" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans [Yahoo! Finance]Yahoo! Finance
- Trump administration strikes deal with AbbVie to cut costs of certain drugs [CNN]CNN
- AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for AmericansPR Newswire
ABBV
Earnings
- 10/31/25 - Beat
ABBV
Sec Filings
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABBV's page on the SEC website